Lietuvos ir Šveicarijos HOSPITEX DIAGNOSTICS KAUNAS - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 4,543,086 | 3,146,318 | 4,452,014 | 3,521,262 | 5,472,941 | 4,894,173 | 5,271,006 | 4,126,428 |
| Profit before tax | 1,582,677 | 829,917 | 1,468,781 | 1,144,650 | 1,547,191 | 1,175,365 | 1,245,945 | 625,868 |
| Net profit | 1,346,493 | 706,449 | 1,248,714 | 972,096 | 1,312,020 | 1,008,044 | 1,198,620 | 597,472 |
| Equity | 2,190,658 | 2,897,036 | 4,145,750 | 3,392,846 | 3,554,866 | 2,457,910 | 3,550,031 | 2,859,001 |
| Liabilities | 725,126 | 322,735 | 537,587 | 598,133 | 1,274,297 | 1,680,437 | 1,448,736 | 1,995,380 |
| Non-current assets | 82,049 | 247,679 | 339,213 | 825,007 | 1,504,643 | 1,489,771 | 1,280,117 | 1,081,536 |
| Current assets | 2,831,679 | 2,969,708 | 4,367,270 | 3,202,337 | 3,365,628 | 2,687,559 | 3,750,706 | 3,807,168 |
| Total assets | 2,913,728 | 3,217,387 | 4,706,483 | 4,027,344 | 4,870,271 | 4,177,330 | 5,030,823 | 4,888,704 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 1,720,263 | 1,119,655 | 906,635 |
| Social insurance contributions | - | - | - | - | - | 99,022 | 116,006 | 117,844 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +57.7% | -30.7% | +41.5% | -20.9% | +55.4% | -10.6% | +7.7% | -21.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 46.2% | 22.0% | 26.5% | 24.1% | 26.9% | 24.1% | 23.8% | 12.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 61.5% | 24.4% | 30.1% | 28.7% | 36.9% | 41.0% | 33.8% | 20.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 29.6% | 22.5% | 28.0% | 27.6% | 24.0% | 20.6% | 22.7% | 14.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 34.8% | 26.4% | 33.0% | 32.5% | 28.3% | 24.0% | 23.6% | 15.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.1 | 0.1 | 0.2 | 0.4 | 0.7 | 0.4 | 0.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 413,008 | 286,029 | 387,132 | 320,115 | 456,078 | 428,685 | 479,182 | 375,130 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Lietuvos ir Šveicarijos HOSPITEX DIAGNOSTICS KAUNAS - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-10-16 | 2025-10-23 | 10093.48 |
| 2022-03-16 | 2022-03-17 | 5759.58 |
Lietuvos ir Šveicarijos HOSPITEX DIAGNOSTICS KAUNAS - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-03-29 | 2026-04-02 | 4.65 |
| 2026-03-19 | 2026-03-27 | 4.65 |
| 2026-03-02 | 2026-03-12 | 0.32 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
HOSPITEX DIAGNOSTICS KAUNAS, UAB, a Private Limited Liability Company (code 110747425), operates in the wholesale of pharmaceutical and medical goods. In 2025, the company generated EUR 4.13 million in revenue and EUR 597.5 thousand in net profit, with a profit margin of 14.5%. Performance softened compared with 2024, when revenue reached EUR 5.27 million and net profit EUR 1.20 million, after an increase from 2023 revenue of EUR 4.89 million and net profit of EUR 1.01 million. Over the two-year period from 2023 to 2025, revenue declined by 15.7% overall, while profitability remained positive throughout. The balance sheet remained solid in 2025, with total assets of EUR 4.89 million, equity of EUR 2.86 million and liabilities of EUR 2.00 million. The equity ratio was 58.5% and debt-to-equity 0.70, indicating a moderate leverage position. Return on equity was 20.9% and return on assets 12.2%. Asset turnover stood at 0.84x. Based on the reported workforce, revenue per employee was EUR 375.1 thousand and profit per employee EUR 54.3 thousand.